(Q42927136)

11 November 2017

A method for evaluating treatment switching criteria in multiple sclerosis (English)

1 reference

11 November 2017

6

Tanuja Chitnis

1 reference

11 November 2017

5

Howard Weiner

1 reference

11 November 2017

Brian C Healy

1

1 reference

11 November 2017

Bonnie I Glanz

series ordinal

2

1 reference

11 November 2017

James Stankiewicz

series ordinal

3

1 reference

11 November 2017

Guy Buckle

series ordinal

4

1 reference

11 November 2017

24 August 2010

1 reference

Multiple Sclerosis Journal

11 November 2017

1 reference

11 November 2017

16

1 reference

11 November 2017

12

1 reference

11 November 2017

1483-1489

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

11 November 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Identifying and treating patients with suboptimal responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Estimating causal effects from epidemiological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Doubly robust estimation in missing data and causal inference models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

21 January 2018

Identifiers

DOI

10.1177/1352458510379245

1 reference

11 November 2017

1 reference